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Lymphadenectomy in 
endometrial cancer
The main ﬁ nding of the MRC ASTEC 
trial (Jan 10, p 125)1 is that there is 
no evidence of beneﬁ t from pelvic 
lympha denectomy for patients with 
endometrial cancer. In this trial, 
surgery consisted of a total abdominal 
hyster ectomy and bilateral salp ingo-
oophor ectomy with or without pelvic 
lympha denectomy by laparotomy. 
However, surgery was also allowed 
by laparoscopy “provided that the 
procedure could be accomplished 
safely and as thoroughly as an open 
procedure”. However, whether laparo -
scopy for endometrial cancer is associ-
ated with a better or worse prognosis 
than open surgery is not known.
Since the primary outcome of the 
study was whether lymphadenectomy 
could improve the survival of women 
with early endometrial cancer when 
compared with surgery without 
lymphadenectomy, we are puzzled 
as to why surgeons were allowed to 
enter patients who underwent a non-
standard surgical procedure. Although 
the proportion who underwent 
laparoscopy was similar in both 
groups (6%), and hence the estimate 
of the diﬀ erence between the groups 
is unlikely to be aﬀ ected, the absolute 
ﬁ gures for survival might be changed 
either positively or negatively.
Total laparoscopic hysterectomy 
is not a standard surgical procedure 
in endometrial cancer. Laparoscopy 
for endometrial cancer can only be 
considered equivalent to an open 
surgical procedure when this has been 
proven by a randomised controlled 
trial. Since we are still awaiting the 
results of the GOG-LAP2 study in early-
stage endometrial cancer—the ﬁ rst 
randomised trial powered for survival 
as a primary outcome—this is not the 
case yet.
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I have some concerns about the ASTEC 
study.1 First, in the standard surgery 
group, surgeons could remove pelvic 
lymph nodes if they believed this 
to be in the woman’s best interest. 
This concession contradicts the aim 
of the study “to test the therapeutic 
eﬀ ect of lymphadenectomy”. The 
ﬁ nal conclusion should thus be 
that lymphadenectomy cannot be 
recommended unless the surgeon 
believes it is in the women’s best 
interest (whatever is meant by that).
Second, inclusion of low-risk 
women (43%) in the study will have 
diluted any possible beneﬁ cial eﬀ ect 
of lymphadenectomy in the high-
risk group. Third, half the patients 
had 12 nodes or fewer removed 
(median 12). Other studies of thera-
peu tic lympha denectomy have a much 
higher median (31).2 Further studies3 
have set 12 nodes as the minimum for 
better staging.
Fourth, despite there being more 
women with high-risk and advanced 
cancer in the lymphadenectomy 
group, radiotherapy was still given 
to an equal number of women in 
each group, resulting in a higher 
proportion of the high-risk-early-
stage (4%) and advanced cancer (8%) 
groups undergoing radiotherapy in 
the standard group. These were even 
higher—5% and 9%, respectively—for 
external-beam radiation therapy. The 
ﬁ nal results were not adjusted for 
this. 
Finally, since randomisation did 
not necessarily prove reliable (there 
was a 10% diﬀ erence in stage IC 
disease between groups), the second 
randomisation (radiotherapy) might 
have invalidated the results of the 
surgical treatments.
I declare that I have no conﬂ ict of interest.
The ASTEC study group1 conclude 
that a systematic lymphadenectomy 
in endometrial cancer cannot be 
recommended as a routine procedure 
because of lack of beneﬁ t in terms of 
recurrence-free and overall survival. 
However, there are several reasons 
why the ASTEC trial did not show 
improved overall survival with 
routine lymphadenectomy.
First, the number of lymph nodes 
resected was insuﬃ  cient in many 
patients. Although the median 
number resected overall was 12, 35% 
of patients in the lymphaden ectomy 
group had nine or fewer lymph nodes 
removed. Cragun and colleagues2 
showed that removal of more than 
11 pelvic nodes had an eﬀ ect on 
overall survival. Chan and colleagues3 
showed that, in intermediate-risk and 
high-risk endometrial cancer, patients 
with more than 10 nodes harvested 
have an improved outcome.
Second, many patients with low-
risk endometrial carcinoma, and 
hence a low risk of lymph-node involv-
e ment, were included (eg, only 41% 
had stage IC–IIB disease, and only 22% 
presented with poorly diﬀ erentiated 
tumours). The high rate of inclusion 
of low-risk patients and the low 
number of lymph nodes removed 
are the reasons for the low rate of 
involved lymph nodes seen in the 
lymphadenectomy group (9%).
Third, the study group did not 
assess the para-aortic nodes. 
However, up to 67% of patients 
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